# A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

> **NCT05138159** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 10 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Donafenib
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT05138159
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05138159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05138159, "A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05138159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*